Fujian Wanchen Biotechnology Group Future Growth
Future criteria checks 6/6
Fujian Wanchen Biotechnology Group is forecast to grow earnings and revenue by 83.3% and 38.9% per annum respectively. EPS is expected to grow by 82.6% per annum. Return on equity is forecast to be 41.6% in 3 years.
Key information
83.3%
Earnings growth rate
82.6%
EPS growth rate
Food earnings growth | 22.2% |
Revenue growth rate | 38.9% |
Future return on equity | 41.6% |
Analyst coverage | Low |
Last updated | 08 Nov 2024 |
Recent future growth updates
Recent updates
Fujian Wanchen Biotechnology Group's (SZSE:300972) Strong Earnings Are Of Good Quality
Nov 04Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972) Stock Rockets 28% But Many Are Still Ignoring The Company
Oct 01Return Trends At Fujian Wanchen Biotechnology Group (SZSE:300972) Aren't Appealing
Sep 30We Think Fujian Wanchen Biotechnology Group (SZSE:300972) Is Taking Some Risk With Its Debt
Aug 04Sentiment Still Eluding Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972)
Jun 06Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 60,733 | 821 | N/A | 2,382 | 1 |
12/31/2025 | 47,061 | 510 | N/A | 1,685 | 2 |
12/31/2024 | 30,970 | 204 | N/A | 1,178 | 2 |
9/30/2024 | 25,006 | 58 | 1,869 | 2,056 | N/A |
6/30/2024 | 17,992 | -76 | 1,383 | 1,590 | N/A |
3/31/2024 | 13,362 | -129 | 1,035 | 1,270 | N/A |
12/31/2023 | 9,294 | -83 | 804 | 1,023 | N/A |
9/30/2023 | 5,091 | -46 | -320 | -65 | N/A |
6/30/2023 | 2,564 | 40 | -298 | 30 | N/A |
3/31/2023 | 1,194 | 76 | -256 | 57 | N/A |
1/1/2023 | 549 | 48 | -246 | 70 | N/A |
9/30/2022 | 546 | 82 | -66 | 128 | N/A |
6/30/2022 | 471 | 38 | 0 | 89 | N/A |
3/31/2022 | 448 | 25 | 6 | 81 | N/A |
1/1/2022 | 435 | 23 | 57 | 99 | N/A |
9/30/2021 | 371 | 4 | 38 | 87 | N/A |
6/30/2021 | 399 | 33 | 66 | 122 | N/A |
3/31/2021 | 417 | 65 | 111 | 157 | N/A |
12/31/2020 | 450 | 96 | 100 | 156 | N/A |
9/30/2020 | 449 | 101 | 115 | 162 | N/A |
6/30/2020 | 460 | 110 | 133 | 171 | N/A |
3/31/2020 | 483 | 130 | 155 | 198 | N/A |
12/31/2019 | 451 | 92 | 138 | 177 | N/A |
9/30/2019 | 442 | 82 | N/A | N/A | N/A |
6/30/2019 | 418 | 74 | 114 | 151 | N/A |
3/31/2019 | 358 | 28 | N/A | N/A | N/A |
1/1/2019 | 343 | 35 | -23 | 102 | N/A |
9/30/2018 | 298 | 15 | N/A | N/A | N/A |
6/30/2018 | 258 | -3 | N/A | 63 | N/A |
3/31/2018 | 265 | 24 | N/A | N/A | N/A |
1/1/2018 | 247 | 16 | N/A | 57 | N/A |
9/30/2017 | 259 | 31 | N/A | N/A | N/A |
6/30/2017 | 267 | 46 | N/A | 100 | N/A |
3/31/2017 | 254 | 52 | N/A | N/A | N/A |
12/31/2016 | 220 | 39 | N/A | 80 | N/A |
9/30/2016 | 189 | 40 | N/A | 59 | N/A |
6/30/2016 | 157 | 30 | N/A | 40 | N/A |
3/31/2016 | 157 | 31 | N/A | 49 | N/A |
12/31/2015 | 157 | 33 | N/A | 58 | N/A |
9/30/2015 | 149 | 30 | N/A | 48 | N/A |
6/30/2015 | 160 | 37 | N/A | 68 | N/A |
3/31/2015 | 145 | 35 | N/A | 67 | N/A |
12/31/2014 | 130 | 34 | N/A | 66 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300972's forecast earnings growth (83.3% per year) is above the savings rate (2.8%).
Earnings vs Market: 300972's earnings (83.3% per year) are forecast to grow faster than the CN market (25.5% per year).
High Growth Earnings: 300972's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 300972's revenue (38.9% per year) is forecast to grow faster than the CN market (13.7% per year).
High Growth Revenue: 300972's revenue (38.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300972's Return on Equity is forecast to be very high in 3 years time (41.6%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/25 17:33 |
End of Day Share Price | 2024/12/25 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fujian Wanchen Biotechnology Group Co., Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Wendan Wang | China International Capital Corporation Limited |
Chenghui Xiong | Huatai Research |
Junhao Fan | Huatai Research |